Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cimaglermin alfa - Acorda Therapeutics

Drug Profile

Cimaglermin alfa - Acorda Therapeutics

Alternative Names: CGF-2; GGF-2 - Acorda; Glial growth factor 2 - Acorda; Neuregulin 1 protein; Neuregulin 1β3; NRG1 protein; Recombinant human glial growth factor-2 (rhGGF 2) - Acorda Therapeutics; rhGGF2 - Acorda

Latest Information Update: 19 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Acorda Therapeutics
  • Class Growth factors; Heart failure therapies; Nerve tissue proteins; Neuregulins
  • Mechanism of Action Epidermal growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Heart failure
  • No development reported Neurological disorders; Stroke

Most Recent Events

  • 27 Feb 2019 Cimaglermin alfa is still in phase I trials for Heart-failure in USA
  • 27 Feb 2019 Cimaglermin alfa - Acorda Therapeutics is available for licensing as of 27 Feb 2019. http://www.acorda.com/#
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Heart-failure in USA (IV, Infusion)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top